Gary Patou's most recent trade in Xenon Pharmaceuticals Inc was a trade of 17,012 Share Option (Right to Buy) done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 17,012 | 17,012 | - | - | Share Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 2,645 | 2,645 | - | - | Restricted Share Units | |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.38 per share. | 22 Nov 2024 | 3,500 | 27,073 (0%) | 0% | 7.4 | 25,830 | Common Shares |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2024 | 3,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2024 | 3,086 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.48 per share. | 22 Nov 2024 | 3,086 | 26,659 (0%) | 0% | 13.5 | 41,599 | Common Shares |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Sale of securities on an exchange or to another person at price $ 41.11 per share. | 22 Nov 2024 | 2,851 | 23,573 (0%) | 0% | 41.1 | 117,205 | Common Shares |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Sale of securities on an exchange or to another person at price $ 41.05 per share. | 22 Nov 2024 | 2,040 | 23,573 (0%) | 0% | 41.1 | 83,742 | Common Shares |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.80 per share. | 22 Nov 2024 | 1,046 | 25,613 (0%) | 0% | 39.8 | 41,631 | Common Shares |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.80 per share. | 22 Nov 2024 | 649 | 26,424 (0%) | 0% | 39.8 | 25,830 | Common Shares |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 15,542 | 15,542 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Sale of securities on an exchange or to another person at price $ 41.05 per share. | 13 Dec 2023 | 7,598 | 4,902 (0%) | 0% | 41.1 | 311,898 | Common Shares |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 18,475 | 18,475 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.68 per share. | 23 Nov 2022 | 2,057 | 25,630 (0%) | 0% | 2.7 | 5,513 | Common Shares |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Sale of securities on an exchange or to another person at price $ 34.33 per share. | 23 Nov 2022 | 2,057 | 23,573 (0%) | 0% | 34.3 | 70,610 | Common Shares |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2022 | 2,057 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Sale of securities on an exchange or to another person at price $ 34.79 per share. | 23 Nov 2022 | 1,937 | 23,573 (0%) | 0% | 34.8 | 67,390 | Common Shares |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.37 per share. | 23 Nov 2022 | 120 | 25,510 (0%) | 0% | 34.4 | 4,124 | Common Shares |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2022 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | 17 Mar 2021 | 100 | 100 (0%) | 0% | 19.5 | 1,949 | Common Shares | |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2020 | 2,057 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Gary Patou | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 28 Oct 2020 | 2,057 | 23,573 (0%) | 0% | 3.8 | 7,734 | Common Shares |